טוען...
Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-bilnd- placebo-controlled exploratory phase 2 trial. Methods: One-hundred forty patients with DLB,...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wiley Subscription Services, Inc., A Wiley Company
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3504981/ https://ncbi.nlm.nih.gov/pubmed/22829268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.23557 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|